Maximum Strength Nasal Decongestant

Description

CVS Health Severe Congestion is a maximum strength nasal spray formulated with oxymetazoline hydrochloride at a concentration of 0.05%. This product is designed for 12-hour relief of nasal congestion. It is presented in a dosage form of a nasal spray, with a net weight of 0.5 fluid ounces (15 mL).

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, and upper respiratory allergies. It also provides temporary relief from sinus congestion and pressure by shrinking swollen membranes, facilitating easier breathing.

There are no teratogenic or nonteratogenic effects associated with this drug as per the available data.

Dosage and Administration

Before the initial use, the protective cap must be removed from the tip, and the pump should be primed by firmly depressing it several times.

For administration, the bottle should be held with the thumb at the base and the nozzle positioned between the first and second fingers. The nozzle should be inserted into the nostril without tilting the head. The rim should be fully depressed with a firm and even stroke while the patient sniffs deeply to ensure proper delivery of the medication. After use, the nozzle must be wiped clean to maintain hygiene.

For adults and children aged 6 to under 12 years, the recommended dosage is 2 to 3 sprays in each nostril, not to exceed every 10 to 12 hours. It is important to note that no more than 2 doses should be administered within a 24-hour period. For children under 6 years of age, consultation with a healthcare professional is advised prior to use.

Contraindications

Use is contraindicated in patients who exceed the recommended dosage or duration of use. Specifically, the product should not be used for more than three consecutive days, as prolonged use may lead to a recurrence or worsening of nasal congestion.

Warnings and Precautions

Healthcare professionals should be aware of the following warnings and precautions associated with the use of this product.

General precautions must be observed to ensure safe usage. It is imperative that the product is not used in excess of the directed dosage. Prolonged use beyond three days is discouraged, as it may lead to a recurrence or worsening of nasal congestion. Users should be informed that temporary discomfort, including burning, stinging, sneezing, or an increase in nasal discharge, may occur during use. Additionally, it is critical to note that sharing this container among multiple individuals may facilitate the spread of infection.

In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is advised.

Healthcare professionals should instruct patients to discontinue use and consult a physician if symptoms persist, ensuring that appropriate follow-up care is provided.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. In clinical practice, it is important to monitor for serious reactions, particularly in individuals with pre-existing conditions.

Patients are advised to stop use and consult a doctor if symptoms persist. Additionally, it is recommended that patients seek medical advice before using this medication if they have a history of heart disease, high blood pressure, diabetes, thyroid disease, or difficulty urinating due to an enlarged prostate gland.

These precautions are essential to ensure the safe use of the medication and to mitigate any potential risks associated with its administration.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Maximum Strength Nasal Decongestant (oxymetazoline spray). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may receive 2 or 3 sprays in each nostril, administered no more than every 10 to 12 hours, with a maximum of 2 doses in any 24-hour period. For children under 6 years of age, it is advised to consult a doctor prior to use.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as they may have altered pharmacokinetics and pharmacodynamics. Close monitoring is recommended to ensure safety and efficacy in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully understood. Therefore, it is essential for women of childbearing potential to seek medical advice to weigh the benefits and risks associated with the use of this medication during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment may require dosage adjustments based on their creatinine clearance levels. It is essential for healthcare professionals to monitor renal function regularly in these patients. Special consideration should be given to those with severe renal impairment, as they may be at increased risk for adverse effects. Renal function tests should be conducted prior to initiating therapy and periodically thereafter to ensure appropriate dosing and to mitigate potential risks associated with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution when administering the medication. It is essential to monitor patients closely for any signs of adverse effects or unexpected reactions.

In the event of suspected overdosage, standard medical practices should be followed. This includes assessing the patient's clinical status and providing supportive care as necessary. Healthcare providers should consider contacting a poison control center or a medical toxicologist for guidance on management strategies tailored to the specific situation.

As there are no documented symptoms or management protocols associated with overdosage for this medication, it is imperative that healthcare professionals remain vigilant and report any unusual occurrences to the appropriate regulatory authorities.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No specific postmarketing experience details are available. As such, there are no additional adverse events or rare case reports to summarize at this time.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of the reach of children. Instruct patients that if the medication is swallowed, they should seek medical help or contact a Poison Control Center immediately.

Patients should be informed to stop using the medication and consult a doctor if symptoms persist. It is important to emphasize that they should not exceed the directed dosage and should not use the medication for more than three days. Frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Patients may experience temporary discomfort, which can include burning, stinging, sneezing, or an increase in nasal discharge. It is crucial to inform patients that using this container by more than one person may increase the risk of spreading infection.

Additionally, healthcare providers should encourage patients to consult a doctor before using the medication if they have any of the following conditions: heart disease, high blood pressure, diabetes, thyroid disease, or difficulty urinating due to an enlarged prostate gland.

Storage and Handling

The product is supplied in a carton that should be retained for future reference on the full labeling. It is essential to store the product at a temperature range of 20° to 25°C (68° to 77°F) to ensure its stability and efficacy. Proper handling and storage conditions must be adhered to in order to maintain the integrity of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Maximum Strength Nasal Decongestant, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)